Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
  1. Home
  3. Cancer Incidence In Patients With Polyglutamine Diseases: A Population-based Study In Sweden.
  1. Home
  3. Cancer Incidence In Patients With Polyglutamine Diseases: A Population-based Study In Sweden.

Related Experiment Video

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden.

Jianguang Ji1, Kristina Sundquist, Jan Sundquist

  • 1Centre for Primary Health Care Research, Lund University and Region Skåne, Lund, Sweden. Jianguang.ji@med.lu.se

The Lancet. Oncology
|April 17, 2012

View abstract on PubMed

Summary
This summary is machine-generated.

Polyglutamine (polyQ) diseases, including Huntington's disease, appear to reduce cancer risk. This suggests a protective mechanism linked to polyQ-tract expansion, warranting further investigation into the underlying biological links.

More Related Videos

Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

Related Experiment Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

Area of Science:

  • Neuroscience
  • Genetics
  • Oncology

Background:

  • Polyglutamine (polyQ) diseases stem from expanded CAG triplet repeats in genes, impacting transcription factors.
  • These diseases include Huntington's disease (HD), spinobulbar muscular atrophy (SBMA), and hereditary ataxia (HA).

Purpose of the Study:

  • To investigate the potential of polyQ diseases to reduce cancer development risk.
  • To explore if a common mechanism underlies cancer protection in polyQ diseases.

Main Methods:

  • Swedish patient data for HD, SBMA, and HA were linked to the Swedish Cancer Registry (1969-2008).
  • Standardized incidence ratios (SIRs) for various cancers were calculated and compared to the general population.
  • Cancer risks were also analyzed in unaffected parents of polyQ disease patients.

Main Results:

  • A total of 1510 HD, 471 SBMA, and 3425 HA patients were identified.
  • Cancer incidence was lower in patients: SIRs were 0.47 for HD, 0.65 for SBMA, and 0.77 for HA.
  • Cancer risk was even lower before polyQ disease diagnosis, and unaffected parents showed general population cancer risk.

Conclusions:

  • Consistently decreased cancer incidence in polyQ diseases suggests a protective mechanism.
  • This protection may be linked to the polyQ-tract expansion characteristic of these diseases.
  • Further research is needed to elucidate the mechanisms connecting cancer and polyQ diseases.